• Zentalis Pharmaceuticals presented interim DENALI Part 1b results for investigational ovarian cancer treatment azenosertib at the ESMO Congress 2026.
• Patients with Cyclin E1-positive platinum-resistant ovarian cancer had longer median overall survival than those with Cyclin E1-negative tumors.
• The findings support Cyclin E1 protein expression as a patient-selection biomarker for azenosertib.
• Safety remained consistent with prior reports, with treatment-related adverse events prompting dose changes or discontinuation in some patients.
• Azenosertib remains under development in the registration-intended DENALI Part 2 study and ASPENOVA Phase 3 confirmatory trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231015PRIMZONEFULLFEED9851795) on October 23, 2026, and is solely responsible for the information contained therein.